RILEMATOVIR

/static/temp/default.svg

Search structure


Synonyms	Jnj-53718678 Rilematovir
Status
Molecule Category	UNKNOWN
UNII	NQ99E8OH3P


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GTQTUABHRCWVLL-UHFFFAOYSA-N
Smiles	CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21
InChI	InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H20ClF3N4O3S
Molecular Weight	500.93
AlogP	3.85
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	7.0
Polar Surface Area	78.89
Molecular species	NEUTRAL
Aromatic Rings	4.0
Heavy Atoms	33.0

Bioactivity

Mechanism of Action	Action	Reference
Fusion glycoprotein F0 inhibitor	INHIBITOR	PubMed PubMed PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Surface antigen	1	-	-	-	-

Assay Description	Organism	Bioactivity	Reference
Antiviral activity against recombinant RSV infected in HeLa cells assessed as reduction in eGFP expression after 3 days by laser microscopic analysis	Respiratory syncytial virus	0.46 nM
Antiviral activity against RSV A infected in HeLa cells	Human respiratory syncytial virus	0.2 nM
Antiviral activity against RSV B infected in HeLa cells	Human respiratory syncytial virus B	0.2 nM
Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microscopic analysis	Respiratory syncytial virus	0.5012 nM
Antiviral activity against RSV Long infected in po dosed cotton rat model assessed as reduction in viral titer in broncho alveolar lavage fluid pretreated for 1 hr followed by viral infection measured after 4 days by plaque reduction assay	Respiratory syncytial virus	0.075 ug.mL-1
Antiviral activity against RSV Long infected in po dosed cotton rat model assessed as reduction in viral titer in lung lavage fluid pretreated for 1 hr followed by viral infection measured after 4 days by plaque reduction assay	Respiratory syncytial virus	0.081 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL4437054
FDA SRS	NQ99E8OH3P
PDB	6YA
PubChem	118892432
SureChEMBL	SCHEMBL17529353

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).